On June 26, 2025, Needham analyst Gil Blum reaffirmed a "Buy" rating for CRISPR Therapeutics (CRSP, Financial). The analyst maintained the price target at $81.00 USD, indicating confidence in the stock's value and potential growth.
This reaffirmation suggests stability in the company's market position as perceived by Needham. Investors tracking CRSP may consider this a positive signal, as the reiterated price target aligns with previous evaluations, showing no change in the analyst's outlook.
CRISPR Therapeutics (CRSP, Financial) continues to be a noteworthy stock for investment portfolios, given the reiterated positive rating by Gil Blum of Needham. The unchanged price target of $81.00 USD underlines the analyst's steady confidence in the biopharmaceutical company's future performance.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 24 analysts, the average target price for CRISPR Therapeutics AG (CRSP, Financial) is $80.80 with a high estimate of $268.00 and a low estimate of $32.00. The average target implies an upside of 74.01% from the current price of $46.43. More detailed estimate data can be found on the CRISPR Therapeutics AG (CRSP) Forecast page.
Based on the consensus recommendation from 29 brokerage firms, CRISPR Therapeutics AG's (CRSP, Financial) average brokerage recommendation is currently 2.2, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
Based on GuruFocus estimates, the estimated GF Value for CRISPR Therapeutics AG (CRSP, Financial) in one year is $34.13, suggesting a downside of 26.49% from the current price of $46.432. GF Value is GuruFocus' estimate of the fair value that the stock should be traded at. It is calculated based on the historical multiples the stock has traded at previously, as well as past business growth and the future estimates of the business' performance. More detailed data can be found on the CRISPR Therapeutics AG (CRSP) Summary page.
